Physician profile
Simon Pinsky
NPI 1174015713
$24,425.88
in general payments reported to CMS, 2019-2025
18 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $857 · 2022: $1,539 · 2023: $1,415 · 2024: $8,509 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $10K · Food and Beverage: $5,934 · Travel and Lodging: $5,017 · Education: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $10,000.00 |
| Food and Beverage | $5,933.50 |
| Travel and Lodging | $5,017.08 |
| Education | $1,079.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,745.31 | 2021-2025 | Micra, Corevalve Evolut R, Aurora Ev-Icd Mri Surescan |
| Abbott Laboratories | $6,902.22 | 2021-2025 | Ensite, Ensite Precision, Assurity |
| Boston Scientific Corporation | $1,870.57 | 2022-2025 | Farapulse, Watchman Access System, Latitude Communicator Power Supply |
| Biosense Webster, INC. | $1,866.48 | 2024-2025 | Carto 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $363.99 | 2023-2024 | Lifevest |
| Cardiva Medical, INC. | $356.63 | 2023-2024 | Cardiva Vascade 5f Vcs, Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Shockwave Medical, INC | $270.42 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cardiovascular Systems INC. | $250.05 | 2021-2023 | Diamondback Peripheral |
| Edwards Lifesciences Corporation | $194.32 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $122.50 | 2022 | |
| Celgene Corporation | $121.12 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $111.26 | 2023 | Camzyos |
| Abiomed | $84.93 | 2022 | |
| Pfizer INC. | $45.10 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $38.96 | 2023-2024 | Uptravi, Opsumit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $38.79 | 2025 | Mynx Control Venous |
| Terumo Medical Corporation | $23.08 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $20.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Pinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.